Dyskinesia

Dopamine-Based Approaches

Pharmaceutical dopamine replacement therapies are an effective palliative treatment for some of the cardinal motor symptoms of PD, but long-term treatment leads to hyperkinetic movements such as dyskinesia, an onerous motor disturbance that has itself been the target of a number of therapeutic approaches.  Research on ameliorating or preventing levadopa-induced dyskinesia has focused on managing drug dosage and blood-levels, and the modulatory affects of other neurotransmitters, such as adenosine.

Responses:
Most Promising Dyskinesia Targets
Alison Urkowitz, MJFF
19 Jun 2009 11:24 AM EST
MJFF recently hosted a brainstorming workshop to discuss ongoing preclinical challenges in dyskinesia research.  A theme of the discussion was that compounds in development to alleviate or ... 
Responses: 5
Q&A with Dr. Gilberto Fisone - Inhibition of mTOR prevents LID
Gilberto Fisone, Karolinska, et al.
16 Jul 2009 02:00 PM EST
In a new paper published today in Science Signaling, Santini et al. demonstrate that inhibition of mTOR signaling by rapamycin can prevent L-DOPA-induced dyskinesia in a PD animal model. Dr. Gilberto ... 
Responses: 4
Comment on Santini et al. 2009
Erwan Bezard, INSERM
16 Jul 2009 02:02 PM EST
This is the follow-up work of our dyskinesia community that furthers the identification of the ERK signaling cascade in LID. Gilberto Fisone and his team show here that one specific target of ERK, ... 
Responses: 2
Linking the Ras-ERK pathway to dyskinesia
Holli Kawadler, MJFF
17 Jul 2009 10:17 AM EST
Dr. Bezard and Dr. Fisone both make interesting points linking mTOR and the Ras-ERK cascade to dyskinesia, and the work raises some questions: ... 
Responses: 1
More on the mTOR story: Ras-ERK to dyskinesia
Gilberto Fisone, Karolinska
17 Jul 2009 06:18 PM EST
Do other downstream effectors of Ras-ERK play prominent roles in LID? Could mTOR be the primary effector?  ... 
great work
Rosario Moratalla
23 Jul 2009 10:28 AM EST
Excellent job!  This investigation by Dr Fisone's group broadens our knowledge of the molecular mechanisms involved in L-DOPA-induced dyskinesias, implicating a new intracellular signaling ... 
Contributions:
GRANT PROGRESS: Pre-clinical Characterization of 5-HT1A/1B Receptor Agonists for the Treatment of Levodopa-induced Dyskinesia: Carta, 2008
Foundation Awards $2.5 Million for Parkinson's Drug Development Projects Led by Academic Investigators
Manolo Carta, Lund, et al.
19 Nov 2009
11/19/2009 INTERIM PROGRESS REPORT Associated Posts: grant award press release abstract  ... 
DeltaJunD overexpression for (temporarily) depriming brain from L-dopa-induced dyskinesia
Striatal Overexpression of DeltaJunD Resets L-3,4-dihydroxyphenylalanine-Induced Dyskinesia in a Primate Model of Parkinson Disease.
Erwan Bezard, INSERM
29 Oct 2009
The Berton et al. manuscript reports the results of a collaborative study conducted with funds from the M.J. Fox Foundation, and involving two laboratories, Berton and Nestler in Dallas and Bezard in ... 
Gene regulation techniques to elucidate the mechanisms of l-DOPA-induced dyskinesia.
Hot Topics@SfN 2009
Christopher Barnum, Emory
20 Oct 2009
l-DOPA is still the standard therapy for PD even though the majority of PD patients experience excessive and abnormal involuntary movements after years of treatment.  Because of this, ... 
more
Research Questions:
How should the dose and timing of LDOPA administration known to impact onset and expression of dyskinesia in humans inform preclinical mechanistic studies?
16 Apr 2009
Validation of new targets is critical for developing novel treatments for dyskinesia.  Before this can happen, optimal testing in dyskinesia models is needed.  Because dyskinesia is a side ... 
Responses: 1
News:
New Research: Dopamine gene therapy without dyskinesia in an MPTP model
While dopamine replacement therapy is the most common and effective treatment for PD, it is accompanied by the debilitating side effects of dyskinesia. However, a new approach using gene therapy ... 
15 Oct 2009
Biovail, Santhera strike Parkinson's drug deal
ZURICH/TORONTO, Aug 24 (Reuters) -- Biovail Corp (BVF.TO) (BVF.N) struck a deal with Swiss biotech Santhera (SANN.S) on Monday, over a drug to treat dyskinesia in Parkinson's disease, marking the ... 
24 Aug 2009
Q&A with Dr. Gilberto Fisone: Inhibition of mTOR blocks L-DOPA induced dyskinesia - UPDATED
Published TODAY - New work from Dr. Gilberto Fisone and colleagues shows blocking mTOR signaling via rapamycin can prevent L-DOPA induced dyskinesia in a mouse model. Read the Q&A with Dr. Fisone ... 
17 Jul 2009
Related Clinical Trials:
Efficacy and Safety of Levetiracetam Versus Placebo on Levodopa-Induced Dyskinesias in Advanced Parkinson's Disease
31 May 2009
The study is designed to measure the efficacy and safety of levetiracetam on levodopa-induced dyskinesias in late-stage Parkinson's disease. The patients are planned to be treated with levetiracetam ... 
Sarizotan in the Treatment of Neuroleptic-Induced Tardive Dyskinesia
31 May 2009
TD is a troublesome and potentially irreversible side effect associated with the use of neuroleptics. While the newer neuroleptics are improved in this regard, they all still carry the ... 
Sarizotan in Parkinson Patients With L-Dopa-Induced Dyskinesia
31 May 2009
The primary purpose of the study is to investigate the anti-dyskinetic effect of several doses of sarizotan in Parkinson patients in order to generate information on the dose-response relationship ... 
more